BioLife Solutions, Inc.
Climate Impact & Sustainability Data (2018)
Reporting Period: 2018
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- Not disclosed
Environmental Achievements
- Not disclosed
Social Achievements
- Not disclosed
Governance Achievements
- Not disclosed
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Not disclosed
Environmental Challenges
- Limited availability of cell and gene therapy starting material, particularly in Europe due to regulations prohibiting monetary reimbursement of donors.
- Variability in donor characteristics (age, disease state, medical history, genetics, lifestyle) impacting starting material quality.
- Variability in leukapheresis collection methods and equipment across clinical sites.
- Insufficient number of target cells in some leukapheresis collections due to factors like chemotherapy and insufficient collection volume.
- Temperature sensitivity of cell therapy products and risk of cold chain disruptions during shipping.
Mitigation Strategies
- Establishing a large, reliable donor database meeting FDA and cGMP/cGTP requirements.
- Optimizing T cell isolation techniques.
- Setting quality criteria for acceptable viable cell counts and immune cell subpopulation ratios.
- Standardizing operating procedures and GMP/GTP compliant collection protocols.
- Partnering with commercial suppliers of human blood products with standardized equipment, protocols, and training.
- Utilizing collection protocols that enrich for the mononuclear cell (MNC) layer and deplete monocytes.
- Employing effective biopreservation media to extend shelf life and optimize quality of starting material.
- Implementing well-controlled freezing and thawing rates and consistent cryopreservation protocols.
Supply Chain Management
Supplier Audits: Not disclosed
Responsible Procurement
- Not disclosed
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Null
Certifications: Null
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Not disclosed